Literature DB >> 8422663

Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion.

S S Hom1, S A Rosenberg, S L Topalian.   

Abstract

Tumor-infiltrating lymphocytes (TIL) were grown in the presence of interleukin-2 from 19 colon carcinoma specimens, including 1 primary lesion and 18 metastatic lesions. These cultures showed a median proliferation of 606-fold (range 13-fold to 28,000-fold) over 49 culture days (range 26-76 days). By phenotype, mature cultures were 69%-99% CD3+ (mean 93%) and contained mixed populations of CD4+ and CD8+ cells (CD4 > CD8 in 10 of 19 cultures). Fresh cryopreserved colon tumors were not lysed by autologous TIL in short-term 51Cr-release assays, and were poorly lysed by lymphokine-activated killer cells. Ten TIL cultures were assayed for cytokine secretion in response to autologous and allogeneic tumors during a 6- to 24-h coincubation. Culture supernatants were tested by ELISA for the presence of granulocyte/macrophage-colony-stimulating factor, interferon gamma, and tumor necrosis factor alpha. Of 10 TIL, 4 secreted at least two of these cytokines specifically in response to autologous and/or HLA-matched fresh allogeneic colon carcinomas, but not to melanomas or HLA-unmatched colon carcinomas. Cytokine secretion was mediated by both CD4+ and CD8+ TIL, and could be inhibited by mAb directed against the appropriate class of MHC antigen. These data provide evidence for specific, MHC-restricted immune recognition of human colon carcinomas by T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422663     DOI: 10.1007/bf01789124

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor.

Authors:  K H Grabstein; D L Urdal; R J Tushinski; D Y Mochizuki; V L Price; M A Cantrell; S Gillis; P J Conlon
Journal:  Science       Date:  1986-04-25       Impact factor: 47.728

2.  Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.

Authors:  P Aebersold; C Hyatt; S Johnson; K Hines; L Korcak; M Sanders; M Lotze; S Topalian; J Yang; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1991-07-03       Impact factor: 13.506

3.  Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion.

Authors:  D J Schwartzentruber; D Solomon; S A Rosenberg; S L Topalian
Journal:  J Immunother (1991)       Date:  1992-07

4.  Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.

Authors:  Y Shimizu; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Authors:  S L Topalian; L M Muul; D Solomon; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

6.  Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.

Authors:  A S Chong; P Scuderi; W J Grimes; E M Hersh
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

7.  Direct cytolysis by partially-purified preparations of immune interferon.

Authors:  S Tyring; G R Klimpel; W R Fleischmann; S Baron
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

8.  Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens.

Authors:  S Carrel; A Schmidt-Kessen; L Giuffrè
Journal:  Eur J Immunol       Date:  1985-02       Impact factor: 5.532

9.  Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

Authors:  R J Barth; J J Mulé; P J Spiess; S A Rosenberg
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

10.  Immunoreactivity by intrinsic lymphoid cells in colorectal carcinoma.

Authors:  J A Werkmeister; E Pihl; A P Nind; G R Flannery; R C Nairn
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640

View more
  14 in total

Review 1.  The immunobiological effects of interleukin-2 in vivo.

Authors:  R A Janssen; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

2.  Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.

Authors:  Simon Turcotte; Alena Gros; Katherine Hogan; Eric Tran; Christian S Hinrichs; John R Wunderlich; Mark E Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2013-07-31       Impact factor: 5.422

3.  Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.

Authors:  Simon Turcotte; Alena Gros; Eric Tran; Chyi-Chia R Lee; John R Wunderlich; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

4.  Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma.

Authors:  W J Bateman; I Donnellan; I A Fraser; L S Wong; A G Morris
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

5.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

6.  Efficient expansion of tumor-infiltrating lymphocytes from solid tumors by stimulation with combined CD3 and CD28 monoclonal antibodies.

Authors:  M J Flens; W M Mulder; H Bril; M B von Blomberg van de Flier; R J Scheper; R A van Lier
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

7.  CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion.

Authors:  R Dadmarz; M K Sgagias; S A Rosenberg; D J Schwartzentruber
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

8.  Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.

Authors:  W M Mulder; M J Stukart; M Roos; R A van Lier; J Wagstaff; R J Scheper; E Bloemena
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

9.  T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.

Authors:  J Shilyansky; M I Nishimura; J R Yannelli; Y Kawakami; L S Jacknin; P Charmley; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 10.  Adoptive-cell-transfer therapy for the treatment of patients with cancer.

Authors:  Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.